Tumor Lysis Syndrome Risk in Burkitt Lymphoma Versus Mantle Cell Lymphoma During Alkylating Therapy: A Propensity-Matched TriNetX Comparative Outcome Analysis
Cureus · 02.06.2026
DOI: 10.7759/cureus.110145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 02.06.2026. Verfasst von Anna Homeniuk und 2 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, University of Pittsburgh Medical Center, Harrisburg, USA. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine, University of Pittsburgh Medical Center, Harrisburg, USA.
- College of Medicine, Drexel University, Philadelphia, USA.
Zitieren
APA
Homeniuk, A., Karthikeyan, G., & Atrash, A. (2026). Tumor Lysis Syndrome Risk in Burkitt Lymphoma Versus Mantle Cell Lymphoma During Alkylating Therapy: A Propensity-Matched TriNetX Comparative Outcome Analysis. Cureus. https://doi.org/10.7759/cureus.110145
Vancouver
Homeniuk A, Karthikeyan G, Atrash A. Tumor Lysis Syndrome Risk in Burkitt Lymphoma Versus Mantle Cell Lymphoma During Alkylating Therapy: A Propensity-Matched TriNetX Comparative Outcome Analysis. Cureus. 2026. doi:10.7759/cureus.110145
BibTeX
@article{Homeniuk2026,
author = {Homeniuk, Anna and Karthikeyan, Gokul and Atrash, Anas},
title = {Tumor Lysis Syndrome Risk in Burkitt Lymphoma Versus Mantle Cell Lymphoma During Alkylating Therapy: A Propensity-Matched TriNetX Comparative Outcome Analysis},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.110145}
}
EUVIMED